• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-K/A filed by Nutriband Inc.

    5/13/25 5:29:18 PM ET
    $NTRB
    Industrial Specialties
    Health Care
    Get the next $NTRB alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    AMENDMENT NO. 1

    to

    FORM 10-K

     

    ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the fiscal year ended January 31, 2025

     

    or

     

    ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from __________ to __________

     

    Commission file number 000-55654

     

    NUTRIBAND INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada   81-1118176
    (State or other jurisdiction of
    Incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    121 South Orange Ave., Suite 1500, Orlando, FL   32801
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (407) 377-6695

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   NTRB   The Nasdaq Stock Market LLC
    Warrants   NTRBW   The Nasdaq Stock Market LLC

     

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

     

    Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. ☐

     

    Note - Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections.

     

    Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

     

    State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $44,975,804 as of July 31, 2024. As of May 13, 2025, the registrant had 11,154,171 shares of common stock outstanding.

     

    DOCUMENTS INCORPORATED BY REFERENCE

     

    None.

     

     

     

     

     

     

    PART IV

     

    Item 15. Exhibits, Financial Statement Schedules.

     

    (1) Financial Statements

     

    (2) Exhibits

     

    Exhibit    
    Number   Description
    1.1   [Reserved]
    3.1A   Articles of Incorporation.(1)
    3.1B   Amendment to Articles of Incorporation, filed May 12, 2016.(1)
    3.1   Certificate of Amendment filed January 21, 2020. (Filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed January 27, 2020).
    3.1C   Certificate of Change, filed with the Nevada Secretary of State on August 4, 2022.(13)
    3.2   By-laws(1)
    3.2B   Amended and Restated By-Laws adopted January 21, 2022.(12)
    4.3   Securities purchase agreement dated October 29, 2019 among the Company, Jefferson Street Capital LLC and Platinum Point Capital LLC(6)
    4.4   Form of convertible 6% promissory note issued pursuant to Exhibit 4.3 (6)
    4.10   Form of Common Stock Purchase Warrant issued to Platinum Point Capital LLC and Jefferson Street Capital LLC(6)
    4.14†   2021 Employee Stock Option Plan.(11)
    4.15†   Form of Stock Option Grant Notice.(11)
    4.16   Form of Common Stock Purchase Warrant issued in the Company’s initial public offering in 2021(9)
    4.17   Form of Warrant issued to the Representative.(14)
    4.18†   2024 Amended and Restated Stock Option Plan, adopted March 20, 2024.(15)
    4.19   Form of Common Stock Purchase Warrant issued in 2024 Equity Financing (18)
    5.1   [Reserved]
    10.1   Share exchange agreement dated January 15, 2016 by and among the Company, Nutriband Limited, an Ireland corporation, and Gareth Sheridan and/or his nominee(1)
    10.4   Acquisition agreement dated April 5, 2018 between the Company and 4P Therapeutics LLC.(3)
    10.5†   Form of agreement with independent directors.(4)
    10.6   Exclusive master distribution agreement dated April 13, 2018 between the Company and EMI-Korea (Best Choice), Inc.(4)
    10.15†   Employment Agreement, dated April 23, 2019, between Gareth Sheridan and the Company.(5)
    10.16†   Employment Agreement, dated April 23, 2019, between Serguei Melnik and the Company.(5)
    10.17†   Employment Agreement, dated February 19, 2019, between Jeffrey Patrick and the Company.(5)
    10.18†   Employment Agreement, dated January 1, 2018, between Sean Gallagher and the Company.(5)
    10.19   Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC.(7)
    10.20   Security Agreement, between the Company and Pocono Coated Products, LLC.(7)
    10.21   Promissory Note Issued by the Company on August 31, 2020 to Pocono Coated Products, LLC.(7)
    10.22   License Agreement, dated December 9, 2020, between the Company and Rambam Med-Tech Ltd.(8)
    10.23   Distribution Agreement, dated March 26, 2021, between the Company and BPM Inno Ltd.(8)
    10.24   Stock Purchase Agreement, dated December 7, 2020, between the Company and BPM Inno Ltd.(8)
    10.25   Amendment No. 1 to Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC(8a)
    10.26   Services  Agreement  dated  October  4,  2021,  between  Active  Intelligence,  LLC  and  Diomics Corporation.(10)
    10.27†   Employment Agreement effective February 1, 2022, between the Company and Gareth Sheridan.(12)
    10.28†   Employment Agreement effective February 1, 2022, between the Company and Serguei Melnik.(12)
    10.29†   Employment Agreement effective February 1, 2022, between the Company and Gerald Goodman.(12)
    10.30   Creditline Promissory Note, dated July 13, 2023. (16)
    10.31   Conversion Agreement, dated December 19, 2023.(17)
    10.32   Form of Subscription Agreement for April 19, 2024 Equity Financing (19)
    10.33   Form of Note Conversion Agreement dated May 13, 202420
    10.35   Commercial Development and Clinical Supply Agreement (“Agreement”), made on January 4, 2023, between Kindeva Drug Delivery, L.P. and 4P Therapeutics, LLC.
    10.36   Amendment No. 1, dated as of February 4, 2025, to the Commercial Development and Clinical Supply Agreement, by and between Kindeva Drug Delivery L.P. and 4P Therapeutics, LLC

    31.1*   Certification of Principal Executive Officer pursuant to Rule 13A-14(A)/15D-14(A) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
    31.2*   Certification of Principal Financial Officer pursuant to Rule 13A-14(A)/15D-14(A) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
    32.1*   Certification of Principal Executive and Financial Officers Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002).

    32.2*

      Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002).

    101.INS*   Inline XBRL Instance Document.
    101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
    101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
    101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
    101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
    101.PRE*  

    Inline XBRL Taxonomy Extension Presentation Linkbase Document.

    104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

     

    1

     

     

    * Filed herewith.
       
    † Executive compensation plan or arrangement.
       
    (1) Filed as exhibit to the Company’s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference.
       
    (2) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on January 27, 2020 and incorporated herein by reference.
       
    (3) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on April 10, 2018 and incorporated herein by reference.
       
    (4) Filed as an exhibit to the Company’s annual report on Form 10-K for the year ended January 3, 2019 which was filed with the Commission on April 19, 2019, and incorporated herein by reference.
       
    (5) Filed as an exhibit to the Company’s Registration Statement on Form S-1/A, which was filed with the Commission on May 19, 2020, and incorporated herein by reference.
       
    (6) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on November 4, 2019, and incorporated herein by reference.
       
    (7) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 4, 2020, and incorporated herein by reference.
       
    (8) Filed as exhibits to the Company’s report on Form 8-K, which was filed with the Commission on March 11, 2021, and incorporated herein by reference.
       
    (8a) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 1, 2021, and incorporated herein by reference.
       
    (9) Filed as Exhibit 4.12 to Amendment 2 to the Company’s Registration Statement on Form S-1, which was filed with the Commission on October 1, 2021.
       
    (10) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on October 12, 2021, and incorporated herein by reference.
       
    (11) Filed as an exhibit to the Company’s Registration Statement on Form S-8, which was filed with the Commission on November 5, 2021, and incorporated herein by reference.
       
    (12) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Commission on January 27, 2022, and incorporated herein by reference.

     

    2

     

     

    (13) Filed as Exhibit 3.1C to the Company’s Current Report on Form 8-K, which was filed with the Commission on August 10, 2022, and incorporated herein by reference.
       
    (14) Filed as an exhibit to the Company’s Registration Statement on Form S-1, which was filed with the Commission on June 26, 2023, and incorporated herein by reference
       
    (15) Filed as Exhibit 4.16 to the Company’s Amendment No. to its Current Report on Form 8-K, which was filed with the Commission on March 28, 2024 and incorporated herein by reference.
       
    (16) Filed as Exhibit 10.30 to the Company’s Current Report on Form 8-K, which was filed with the Commission on July 14, 2023.
       
    (17) Filed as Exhibit No. 10.31 to the Company’s Current Report on Form 8-K, which was filed with the Commission on December 29, 2023.
       
    (18) Filed as Exhibit No.  4.19 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024.
       
    (19) Filed as Exhibit No. 10.32 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024.
       
    (20) Filed as Exhibit No. 10.33 to the Company’s Current Report on Form 8-K, which was filed with the Commission on May 21, 2024.

     

    (b) Financial Statement Schedules

     

    All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto.

     

    ITEM 16. FORM 10-K SUMMARY

     

    Not applicable.

     

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: May 13, 2025

     

      NUTRIBAND INC.
       
      By: /s/ Gareth Sheridan
        Gareth Sheridan
        Chief Executive Officer
         
      By: /s/ Gerald Goodman 
        Gerald Goodman
        Chief Financial Officer
    (Principal Financial and Accounting Officer)

     

    Signature   Title   Date
             
    /s/ Gareth Sheridan   Chief Executive Officer and Director   May 13, 2025
    Gareth Sheridan        
             
    /s/ Serguei Melnik   Director   May 13, 2025
    Serguei Melnik        
             
        Director    
    Sergei Glinka        
             
    /s/ Radu Bujoreanu   Director   May 13, 2025
    Radu Bujoreanu        
             
    /s/ Mark Hamilton    Director   May 13, 2025
    Mark Hamilton        
             
    /s/ Stefani Mancas   Director   May 13, 2025
    Stefani Mancas        
             
    /s/ Irina Gram   Director   May 13, 2025
    Irina Gram        

     

    4

     

    10-K/A No 0001676047 true FY 0001676047 2024-02-01 2025-01-31 0001676047 us-gaap:CommonStockMember 2024-02-01 2025-01-31 0001676047 ntrb:WarrantsMember 2024-02-01 2025-01-31 0001676047 2024-07-31 0001676047 2025-05-13 iso4217:USD xbrli:shares
    Get the next $NTRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTRB

    DatePrice TargetRatingAnalyst
    1/22/2025$13.00Outperform
    Noble Capital Markets
    More analyst ratings

    $NTRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Nutriband with a new price target

      Noble Capital Markets initiated coverage of Nutriband with a rating of Outperform and set a new price target of $13.00

      1/22/25 9:24:55 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nutriband CEO Publishes Letter to Shareholders

      ORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024 and the potential outlook for 2025. The full text of the letter is below. Dear Shareholders, Following the filing of our annual report as we wrap up a successful year packed with milestones and advances towards the commercialization of our AVERSA technology, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2024 and into 2025. Many of you have been with us from the beginning an

      4/30/25 7:30:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

      ORLANDO, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology. The Macao Intellectual Property Office granted patent J/9010 on February 11, 2025 as recorded in Macao Official Bulletin No. 10 on March 5, 2025. Macao is a Special Administrative Region (SAR) of the People's Republic of China that has its own patent system and patent laws

      4/11/25 7:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • UPDATE – Nutriband Signs Associate Partnership with Charlotte FC

      ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the "Company")(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC. The Company intends to use the Associate partnership to build visibility for its brands such as AI Tape which is manufactured locally in the Charlotte area. "We are very excited to partner with an organization such as Charlotte FC as an Associate Partner. Manufacturing many of our products locally in the Charlotte region through our Pocono subsidiary makes this relationship special.'' AI Tape is manufactured in the USA at the Co

      4/4/25 5:41:36 PM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Financials

    Live finance-specific insights

    See more
    • Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo

      5/10/24 9:00:00 AM ET
      $CANF
      $NTRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Nutriband Inc. Commences Trading on Upstream Under NTRB

      Nutriband among the first issuers to dual list on UpstreamORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".Global investors can now trade by downloading Upstream from their preferred app sto

      1/5/23 6:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Inc. Will Be the First Company to Dual List on Upstream

      Trading scheduled to Commence on Upstream January 5, 2023ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval."We are proud to have a trailblazer like Nutriband as the first company to dual list on Upstream and offer its shares to an international investor-base seeking streamlined access to U.S. companies," says Upstream Co-Founder Mark Elenowitz.The dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, u

      12/30/22 6:30:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Goodman Gerald

      4 - NutriBand Inc. (0001676047) (Issuer)

      12/2/24 3:49:25 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by President and Secretary Melnik Serguei

      4 - NutriBand Inc. (0001676047) (Issuer)

      11/29/24 1:58:08 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by CEO Sheridan Gareth

      4 - NutriBand Inc. (0001676047) (Issuer)

      11/29/24 1:11:33 PM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by Nutriband Inc.

      10-K/A - NutriBand Inc. (0001676047) (Filer)

      5/13/25 5:29:18 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 10-K filed by Nutriband Inc.

      10-K - NutriBand Inc. (0001676047) (Filer)

      4/28/25 5:21:20 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NutriBand Inc. (0001676047) (Filer)

      4/9/25 11:41:41 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Leadership Updates

    Live Leadership Updates

    See more
    • Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

      The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri

      5/16/24 7:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Nutriband Inc.

      SC 13D/A - NutriBand Inc. (0001676047) (Subject)

      9/19/24 11:38:15 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Nutriband Inc.

      SC 13G - NutriBand Inc. (0001676047) (Subject)

      2/13/24 8:33:52 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Nutriband Inc.

      SC 13G - NutriBand Inc. (0001676047) (Subject)

      2/12/24 3:57:44 PM ET
      $NTRB
      Industrial Specialties
      Health Care